Alcon

Aerie Pharmaceuticals appoints Huan Sheng director of Clinical Research and Drug Safety

Wednesday, February 8, 2017

Aerie Pharmaceuticals, a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, has announced the appointment of Huan Sheng, M.D., Ph.D., as director of Clinical Research and Drug Safety, reporting to Kristine Erickson, O.D., Ph.D., Aerie’s vice president of Clinical Research.

[Read More]

Align Biopharma launched as industry standards group

Monday, January 30, 2017

Six of the top 25 largest global pharmaceutical companies announced the formation of Align Biopharma, a new group dedicated to setting technology standards that will make it faster and easier for healthcare professionals (HCPs) to connect with the life sciences industry. Founding members, with input from across the industry, will develop open standards and solutions for companies to streamline how HCPs get the drug and treatment information they need to deliver improved care to patients.

[Read More]

Novartis cuts pharmaceutical division in half

Friday, May 20, 2016

Novartis has announced changes to focus its Pharmaceuticals Division by creating two business units reporting to the CEO: Novartis Pharmaceuticals and Novartis Oncology. These business units will form the Innovative Medicines Division at Novartis. The leader of each business will join the Executive Committee of Novartis (ECN) effective July 1, 2016. Paul Hudson will be appointed CEO, Novartis Pharmaceuticals, and Bruno Strigini will become CEO, Novartis Oncology. Both will report directly to Joseph Jimenez, CEO of Novartis. With these changes, David Epstein, currently Division Head and CEO, Novartis Pharmaceuticals, has decided to leave Novartis. 

[Read More]

Perrigo names board of directors

Friday, December 20, 2013

Dublin, Ireland-based Perrigo has announced the appointment of its board of directors, effective until Perrigo’s annual general meeting scheduled for November 2014. The appointment of the Perrigo board follows the completion of Perrigo’s acquisition of Elan in a cash and stock transaction valued at approximately $8.6 billion. The transaction will create a global healthcare company with a growth profile.

[Read More]